Dystrophin immunity in Duchenne's muscular dystrophy. - Wikidata - awgldk - TriplyDB

Dystrophin immunity in Duchenne's muscular dystrophy.

Dystrophin immunity in Duchenne's muscular dystrophy.

http://www.wikidata.org/entity/Q41590387

about

An integrative computational systems biology approach identifies differentially regulated dynamic transcriptome signatures which drive the initiation of human T helper cell differentiation Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials Current and emerging treatment strategies for Duchenne muscular dystrophy The emerging role of viral vectors as vehicles for DMD gene editing Adeno-associated Virus as a Mammalian DNA Vector Duchenne Muscular Dystrophy: From Diagnosis to Therapy Developments in the treatment of hemophilia B: focus on emerging gene therapy The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy Current prospects and challenges for epilepsy gene therapy Gene therapy on the move Antisense oligonucleotides: treating neurodegeneration at the level of RNA Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance Advances in gene therapy for muscular dystrophies AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD Passive immunization against HIV/AIDS by antibody gene transfer.Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder.Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping HLA engineering of human pluripotent stem cells Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel Therapies Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms Influence of immune responses in gene/stem cell therapies for muscular dystrophies.Gene and cell-mediated therapies for muscular dystrophy.Stem cell transplantation for muscular dystrophy: the challenge of immune response.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.PKC theta ablation improves healing in a mouse model of muscular dystrophy.The effects of low levels of dystrophin on mouse muscle function and pathology Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies Gene therapy for inherited muscle diseases: where genetics meets rehabilitation medicine.Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy Progress and prospects of gene therapy clinical trials for the muscular dystrophies.Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Dystrophin quantification: Biological and translational research implications.

P2860

Q21093377-D6927B87-5EBD-4795-B37E-3145D917F33F Q26741409-C23543D6-698D-43BF-B703-E56251B965AA Q26741535-44D424C6-80BB-4BFC-B565-AAFDCCBBD796 Q26746647-AD3AE627-EF3E-4602-9C88-7EA324678AF2 Q26782605-90288EE8-AD91-428E-A596-05373FF68F34 Q26784259-CAE32BAB-6CA7-4600-AE32-468D939E7F45 Q26823376-CC9656D5-1517-4280-8DD9-EFDBED4A0EFD Q26827638-E895F016-81B0-4C3B-AEE8-DB6F5B033FD9 Q27002627-016080B5-9FB1-4774-BD49-0E24C1222B1F Q27007012-402A7196-37C0-43C3-86EA-8E73E78F0623 Q27007056-C07EDD95-82FE-48FD-82FA-1FB81A6DE047 Q27012320-6C8E2278-AC02-4E1A-BB7B-FFFCBB688D07 Q27300915-5F9B717F-A75C-42FF-A014-32159D94AF6F Q27317882-2490073E-6ECC-4AE4-B4CA-81248BED8B86 Q28073994-22FE2D10-E660-4151-A963-AF9563C1B688 Q28283362-B7B995EF-5158-4E16-B6A7-96D4E786533A Q28389778-2056AD1D-72F5-42D1-A46C-29CAD629DC87 Q30358434-5AFF04FC-4F5D-4E0B-929B-5C3814F9E1D4 Q30500346-CDFB5B33-D09A-4AC0-B3EF-BDC8B7CB5579 Q30514014-C0C4D5D9-4492-430D-8FDC-E7C95EF0BAF7 Q30540471-7328686D-7148-4265-905A-3E9439E57DD0 Q33608478-3A34E22F-FA02-4078-BDA6-B5F291B9A455 Q33678893-52CEA9CF-75B1-48D2-992E-EC0E706A2AD5 Q33685967-8919A450-1243-4AA6-9B35-3DF2902B83F1 Q33736192-A3978E4A-0F8B-4E46-B2ED-BC034759DC4C Q33831193-AA1136B9-1367-4AE3-9281-715256DAA027 Q33902416-4CA2F43C-265F-407A-9ECD-E326D01E2F34 Q33902499-20F8706C-4299-4321-B6BF-8DBA1F98A3BB Q33926944-C9427F54-7596-4D21-8D6F-0E1D7A14B4FC Q33938435-FD34A3A0-5A68-404E-A37F-57B621D61740 Q34041966-1A3F6A10-B995-48E8-A1B5-E6358F2CACE7 Q34163572-EB2E9D2B-223A-47AA-A589-5B7F6D98245D Q34168463-FD977610-B103-4A1A-82AA-7E3DFC4F5EE4 Q34215825-3C82E6C3-6ADC-4E64-9F41-87A4B1829661 Q34340857-CEF2AB8C-83CD-44EE-8776-8A4C95646376 Q34370111-1369CBB0-7D01-4145-9D16-96CF228094A7 Q34409434-F88F58C5-A92D-4BD4-AB46-F182DE6B4488 Q34497471-2791CEFD-557A-45E1-AC7E-F2039A5EF79D Q34566454-4C0313CD-ECDA-4159-B2F8-46097DCA58AA Q34591203-CF5E5C69-B0F6-4D33-BD38-B9A2825EA2E8

P2860

Dystrophin immunity in Duchenne's muscular dystrophy.

http://www.wikidata.org/entity/Q41590387

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Dystrophin immunity in Duchenne's muscular dystrophy.

@en

type

label

Dystrophin immunity in Duchenne's muscular dystrophy.

@en

prefLabel

Dystrophin immunity in Duchenne's muscular dystrophy.

@en

P1433

Q41590387-D6C33371-7D63-46ED-A0D5-9A53783FB235

P1476

Q41590387-741A8593-AA62-49D6-BBED-9EF4A84C5666

P2093

Q41590387-0524C94D-148A-4D19-B903-A07E1EA23834

Q41590387-0DCFA2F9-AED8-4AFD-AFE2-96C16980182D

Q41590387-3A1520D4-D99B-49FD-9745-6DFA2106E601

Q41590387-4071193F-C6A0-4DA2-BAB2-39152BEA9AEE

Q41590387-494DD881-6873-49A8-9808-037DCFB7410B

Q41590387-4CEA74AE-CA59-4AAA-94A0-D047BAE2E7FD

Q41590387-651C8187-0109-4E5D-AFA0-D49BAF6DD131

Q41590387-93785A1C-D71A-4709-B30C-0E2A4D228B9B

Q41590387-A0E87A90-83C3-45DB-8147-09267DE8D6FC

Q41590387-A74A6DDB-BF01-42F4-A8CB-DB423EA0C7B6

P2860

Q41590387-0E2CE1A3-BBE2-410E-A222-89C334AC26DC

Q41590387-27BAA016-D647-4B3E-8731-AE0034D9D01F

Q41590387-28880FA8-B385-4E2E-B6EF-B59A1462418F

Q41590387-45A0E1BC-A76F-494B-BC53-030319BFA485

Q41590387-58FF8AC3-D2CB-44C3-B63C-6455B8117BBC

Q41590387-627E79E9-5645-416A-813A-AF9C741136ED

Q41590387-73BBF3AB-FECF-40EA-89F6-A401C4D6CD1B

Q41590387-7412AF8A-9128-44BA-A6A4-2F5724F41106

Q41590387-800C718E-A535-42A4-BED1-940A19F6FE7A

Q41590387-80969D7E-85F1-4DBA-8A56-FBD46AC36733

P304

Q41590387-4590E2F5-0004-48D1-85DE-30C1BBEF96C8

P31

Q41590387-2C678B4E-66F8-41EF-92BC-022EA8198BEF

P356

Q41590387-006B8240-4F76-4FAB-B611-5BCB9409792F

P407

Q41590387-C1D12B45-22DE-4A54-AF00-B99D9DCE553C

P433

Q41590387-98B1252B-6623-44C5-A84D-876725489B4B

P478

Q41590387-C969E5BA-F627-47FD-B123-70FBFEC8B8BF

P50

Q41590387-D545B874-CE28-4BA8-9F84-790255A58DB1

P577

Q41590387-F4E99D21-D699-4F47-8D5E-E535133C03A4

P698

Q41590387-A93DA14F-E7E4-43BC-A28B-179492BD1923

P932

Q41590387-8B5CAC2C-92D9-4255-A123-C9D6D1C78F6B

P356

P1433

The New England Journal of Medicine

P1476

Dystrophin immunity in Duchenne's muscular dystrophy

@en

P2093

Chengwen Li

http://www.w3.org/2001/XMLSchema#string

Chris Shilling

http://www.w3.org/2001/XMLSchema#string

Christopher M Walker

http://www.w3.org/2001/XMLSchema#string

Dawn Bowles

http://www.w3.org/2001/XMLSchema#string

Gloria Galloway

http://www.w3.org/2001/XMLSchema#string

Jade Samulski

http://www.w3.org/2001/XMLSchema#string

Jerry R Mendell

http://www.w3.org/2001/XMLSchema#string

Juan Li

http://www.w3.org/2001/XMLSchema#string

K Reed Clark

http://www.w3.org/2001/XMLSchema#string

Katherine Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial

Safety and efficacy of gene transfer for Leber's congenital amaurosis

T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides

Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial

Effect of gene therapy on visual function in Leber's congenital amaurosis

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.

Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers.

Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy.

P304

1429-1437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1000228

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20925545

http://www.w3.org/2001/XMLSchema#string

P932

3014106

http://www.w3.org/2001/XMLSchema#string